Results 81 to 90 of about 4,732,777 (361)

Comment on ‘An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers’ by Fukui et al. [PDF]

, 2023
Yoshiya Horimoto
openalex   +1 more source

Tumor‐stromal crosstalk and macrophage enrichment are associated with chemotherapy response in bladder cancer

FEBS Open Bio, EarlyView.
Chemoresistance in bladder cancer: Macrophage recruitment associated with CXCL1, CXCL5 and CXCL8 expression is characteristic of Gemcitabine/Cisplatin (Gem/Cis) Non‐Responder tumors (right side) while Responder tumors did not show substantial tumor‐stromal crosstalk (left side). All biological icons are attributed to Bioicons: carcinoma, cancerous‐cell‐
Sophie Leypold, Janik Riese, Lancelot Seillier, Mark Kühnel, Julia Pannhausen, Charlotte O. J. Fröhlich, Christian Martin, Peter Boor, Matthias Saar, Danny D. Jonigk, Nadine T. Gaisa, Michael Rose   +11 more
wiley   +1 more source

Neoadjuvant Therapy for Rectal Cancer [PDF]

Diseases of the Colon & Rectum, 2018
A 63-year-old man presents to his primary care doctor with a one-month history of blood in his stools. He is referred for a colonoscopy and found to have a friable mass along the anterior wall just proximal to the second rectal fold. A biopsy confirms moderately-differentiated adenocarcinoma.
Ira L, Leeds, Sandy H, Fang
openaire   +2 more sources

Characterization of Microplastics in Human Gastric Cancer and Control Tissues and Analysis of Associated Genetic Features

Advanced Healthcare Materials, EarlyView.
This study characterizes the presence of microplastics in human normal gastric, para‐tumor, and gastric tumor tissue and confirms the association between microplastic exposure and lymph node metastasis in gastric cancer. This study explores the transcriptomic changes induced by microplastic exposure, laying the foundation for further investigation into
Liqiao Chen, Jialin Li, Yan Wu, Han Bao, Xuesong Yang, Guoqing Lv, Ke Ji, Ji Zhang, Xiaojiang Wu, Kai Zhou, Jieli Xu, Jiatian Tang, Xiyuan Han, Anqiang Wang   +13 more
wiley   +1 more source

Neoadjuvant therapy for gastroesophageal adenocarcinoma

World Journal of Clinical Oncology, 2016
Gastric and esophageal adenocarcinomas are one of the main causes of cancer-related death worldwide. While the incidence of gastric adenocarcinoma is decreasing, the incidence of gastroesophageal junction adenocarcinoma is rising rapidly in Western countries.
Emmanuelle, Samalin, Marc, Ychou
openaire   +2 more sources

Mitochondrial Calcium Uniporter Drives Chemoresistance in Pancreatic Cancer via Glutathione‐Mediated Stemness Maintenance

Advanced Science, EarlyView.
PDAC has a poor prognosis due to chemoresistance. We revealed that MCU upregulation is associated with chemoresistance and stemness in PDAC. MCU‐mediated Ca2+ influx induced ER stress, activating the PERK‐ATF4/NRF2 axis to enhance PSAT1/SLC711 expression and glutathione synthesis, reducing ROS and maintaining stemness.
Zekun Li, Chenyang Meng, Guangcong Shen, Yueying Shan, Junjin Wang, Diliyaer Abudukeremu, Rui Zhao, Bo Ni, Chao Xu, Xiaofan Guo, Jun Yu, Kaiyuan Wang, Shengyu Yang, YunZhan Li, Yongjie Xie, Tianxing Zhou, Jihui Hao, Xiuchao Wang   +17 more
wiley   +1 more source

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

Advanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao, Qinyuan Liu, Zhongwei Xin, Zhiyao Zhou, Mingjie Lin, Di Chen, Zhixing Hao, Yongyuan Chen, Wenxuan Wu, Shuyang Zhang, Xiaoke Chen, Xia Xu, Jinfan Li, Wei Lin, Yuhao Lu, Dang Wu, Pin Wu   +16 more
wiley   +1 more source

Three‐Year Follow‐Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer‐Associated Fibroblast Heterogeneity Corresponding to PD‐1 Blockade Efficacy

Advanced Science, EarlyView.
Heterogeneous cancer‐associated fibroblasts orchestrate dual immune microenvironments in LAGC. Abstract The potential for immunotherapy in patients with locally advanced gastric cancer (LAGC) is recently confirmed. To report the 3‐year follow‐up data are aimed from a novel clinical trial. This is a prospective single‐arm phase II trial.
Yao Lin, Xiong Sun, Chengguo Li, Ming Yang, Ke Wu, Ke Liu, Anshu Li, Xiaoming Shuai, Kailin Cai, Zheng Wang, Guobin Wang, Peng Zhang, Jianfeng Shen, Kaixiong Tao, Yuping Yin   +14 more
wiley   +1 more source

Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer [PDF]

, 2023
Carsten Denkert, Chiara Lambertini, Peter A. Fasching, Katherine L. Pogue–Geile, Max S. Mano, Michael Untch, Norman Wolmark, Chiun‐Sheng Huang, Sibylle Loibl, Eleftherios P. Mamounas, Charles E. Geyer, Peter C. Lucas, Thomas Boulet, Chunyan Song, Gail D. Lewis Phillips, Małgorzata Nowicka, Sanne de Haas, Mark Basik   +17 more
openalex   +1 more source

Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy

Journal of Clinical Oncology, 2022
J. García-Aguilar, S. Patil, M. Gollub, Jin K. Kim, J. Yuval, Hannah M Thompson, F. Verheij, D. Omer, Meghan E. Lee, R. Dunne, J. Marcet, P. Cataldo, B. Polite, Daniel O. Herzig, D. Liska, S. Oommen, C. Friel, C. Ternent, A. Coveler, S. Hunt, A. Gregory, M. Varma, B. Bello, J. Carmichael, J. Krauss, A. Gleisner, P. Paty, M. Weiser, G. Nash, E. Pappou, José G. Guillem, L. Temple, I. Wei, M. Widmar, Sabrina T. Lin, N. Segal, A. Cercek, R. Yaeger, J. Smith, K. Goodman, A. Wu, L. Saltz   +41 more
semanticscholar   +1 more source